Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Biomea Fusion Inc (BMEA)

Biomea Fusion Inc (BMEA)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
2.19 -0.11 (-4.78%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 2.18 -0.01 (-0.46%) 19:55 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.15
Day High
2.41
Open 2.32
Previous Close 2.30 2.30
Volume 747,000 747,000
Avg Vol 800,830 800,830
Stochastic %K 82.67% 82.67%
Weighted Alpha -73.99 -73.99
5-Day Change +0.50 (+29.59%) +0.50 (+29.59%)
52-Week Range 1.53 - 13.43 1.53 - 13.43
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,653
  • Shares Outstanding, K 37,572
  • Annual Sales, $ 0 K
  • Annual Income, $ -138,430 K
  • EBIT $ -144 M
  • EBITDA $ -142 M
  • 60-Month Beta -0.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.62

Options Overview Details

View History
  • Implied Volatility 135.46% ( -78.22%)
  • Historical Volatility 111.21%
  • IV Percentile 72%
  • IV Rank 12.82%
  • IV High 747.02% on 04/14/25
  • IV Low 45.55% on 06/06/24
  • Put/Call Vol Ratio 0.12
  • Today's Volume 1,074
  • Volume Avg (30-Day) 362
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 11,217
  • Open Int (30-Day) 16,143

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.84
  • Number of Estimates 2
  • High Estimate -0.82
  • Low Estimate -0.85
  • Prior Year -1.09
  • Growth Rate Est. (year over year) +22.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.53 +43.14%
on 04/09/25
Period Open: 2.69
2.65 -17.41%
on 03/26/25
-0.50 (-18.59%)
since 03/25/25
3-Month
1.53 +43.14%
on 04/09/25
Period Open: 4.41
4.48 -51.12%
on 01/27/25
-2.22 (-50.34%)
since 01/24/25
52-Week
1.53 +43.14%
on 04/09/25
Period Open: 10.47
13.43 -83.69%
on 05/16/24
-8.28 (-79.08%)
since 04/25/24

Most Recent Stories

More News
IVEY PMI Reading Due Next Week in Canada

IVEY PMI Reading Due Next Week in Canada U.S. Monday Economic Lookahead Consumer credit ...

WDFC : 223.37 (-0.55%)
TLRY.TO : 0.69 (+1.47%)
JPM : 243.55 (-0.45%)
AGF-B.TO : 9.94 (-0.20%)
MAMA : 6.46 (+3.19%)
CCA.TO : 64.63 (-0.05%)
BYRN : 23.17 (+1.00%)
RPM : 104.44 (-1.05%)
DAL : 41.58 (-1.05%)
LEVI : 16.08 (+0.75%)
SMPL : 35.23 (-0.54%)
PLAY : 19.51 (+0.77%)
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BMEA : 2.19 (-4.78%)
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

BMEA : 2.19 (-4.78%)
Biomea Fusion Announces Leadership Transition

BMEA : 2.19 (-4.78%)
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

BMEA : 2.19 (-4.78%)
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BMEA : 2.19 (-4.78%)
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

BMEA : 2.19 (-4.78%)
Biomea Fusion to Become a Diabetes & Obesity Medicines Company

BMEA : 2.19 (-4.78%)
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

BMEA : 2.19 (-4.78%)
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BMEA : 2.19 (-4.78%)

Business Summary

Biomea Fusion Inc. is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion Inc. is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 2.61
2nd Resistance Point 2.51
1st Resistance Point 2.35
Last Price 2.19
1st Support Level 2.09
2nd Support Level 1.99
3rd Support Level 1.84

See More

52-Week High 13.43
Fibonacci 61.8% 8.88
Fibonacci 50% 7.48
Fibonacci 38.2% 6.08
Last Price 2.19
52-Week Low 1.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective